Board of Directors

Nancy Miller-Rich

Nancy Miller-Rich

Director, Executive Chair

  • 30+ years senior pharma executive with experience in global business development, commercial strategy & sales (Direct P&L involvement in the $38 B pharmaceutical division at Merck)
  • Former Global Sr. VP BD at Merck, VP at Schering-Plough, Sandoz, Sterling Drug
  • At Merck closed approximately 300 deals producing $10 B of value creation

           

Ahmad Doroudian, PhD

Ahmad Doroudian, PhD

Director, CEO

  • 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
  • Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
  • Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®

 

Celia Economides, MPH

Celia Economides, MPH

Director

  • 15 year senior executive-level experience developing corporate strategy and financing
  • Senior executive roles BIO, Biomarin (NASDAQ: BMRN) and Aurinia (NASDAQ: AUPH)
  • Most recently co-raised $170 M at Aurinia (NASDAQ: AUPH)

          

Ali Ardakani

Ali Ardakani

Director

  • 18 years experience as a biotech entrepreneur, CEO, co-founder and developer
  • Sr. VP Device & BD at AIT Therapeutics, CEO of Novateur Ventures, Co-founder of Lexi Pharma
  • Responsible for raising over $100 M in equity in several ventures
  • Led approval for two medical devices 510(k)s and several INDs and clinical trials
  • Vice-Chair of Life Sciences BC, Creative Destruction Lab, EIR at Innovation Blvd